20-F: CytoMed Therapeutics Reports Full Year 2024 Results, Highlights Clinical Trial Progress and Financial Position

CytoMed Therapeutics Limited announces its full year 2024 financial results, highlighting ongoing clinical trial advancements and a solid financial foundation for future growth.

Summary

• CytoMed Therapeutics Limited reported a loss of S$2.52 million for the year ended December 31, 2024.
• The company is focused on developing cell-based immunotherapies for cancer and degenerative diseases.
• Revenue from private blood banking services started at S$69,501 after the acquisition of Cellsafe International Sdn Bhd.
• Research expenses increased to S$1.91 million, driven by clinical trial expenses and employee benefits.
• The company received co-funding support for its ANGELICA Trial from the MOH Singapore.
• Two patients have been successfully dosed in the ANGELICA Trial as of the report date.
• The company had cash and bank balances of S$4.97 million as of December 31, 2024.
• The company is pursuing an investigational new drug application for CTM-GDT with the US FDA.
• A research collaboration agreement was entered into with Sengkang General Hospital for CTM-MSC.
• The company is targeting a Phase I clinical trial submission for CTM-MSC in the second half of 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive developments such as the start of revenue generation and co-funding for clinical trials, the company is still operating at a loss and faces significant risks and challenges in the biopharmaceutical industry.

Positives

• The company started generating revenue from private blood banking services.
• The company received co-funding support for its ANGELICA Trial from the MOH Singapore.
• Two patients have been successfully dosed in the ANGELICA Trial as of the report date.
• The company had cash and bank balances of S$4.97 million as of December 31, 2024.
• A research collaboration agreement was entered into with Sengkang General Hospital for CTM-MSC.
• The company is targeting a Phase I clinical trial submission for CTM-MSC in the second half of 2025.

Negatives

• The company reported a loss of S$2.52 million for the year ended December 31, 2024.
• Research expenses increased to S$1.91 million, driven by clinical trial expenses and employee benefits.

Risks

• The company is a clinical stage biopharmaceutical company with no products approved for commercial sale.
• The company expects to continue to incur significant losses for the foreseeable future.
• The company may require additional capital, which, if available, may cause dilution to shareholders.
• The company's business is subject to the effects of pandemics, health epidemics, and outbreaks of infectious diseases.
• The company's business depends upon the success of its CTM-N2D, iPSC-gdNKT, CTM-GDT and CTM-MSC product candidates in obtaining regulatory approval and being commercialized.
• The company's pre-clinical studies may experience delays or may not progress to clinical trials.
• The company's clinical trials may experience delays or may not be successful.
• The company's product candidates may have undesirable side effects.
• The company may not identify or develop other product candidates.
• The company relies on third parties to assist it in conducting its clinical trials.
• The company may fail to successfully compete with academic institutions and other biopharmaceutical companies.
• The company will need to increase the size of its organization, and it may experience difficulties in managing growth.
• The company may fail to attract and retain senior management, clinical, and key scientific personnel.
• The company may incur substantial liabilities as a result of product liability lawsuits.
• The company's business involves the use of biohazardous materials.
• The company is exposed to information technology and cyber security risks and disruption of service.
• The company's cGMP Facility may be affected by circumstances beyond its control.
• The company's current cGMP Facility may not be sufficient to handle the large-scale commercial manufacture and production of product candidates.
• The company's manufacturing process is complex, and it may encounter challenges in production of its product candidates.
• The company is highly reliant on certain key suppliers for certain steps of its manufacturing processes.
• The company relies on the storage of its cell bank for the engineered K562 cells and peripheral blood mononuclear cells, and any damage or loss to them would cause delays in its clinical trials.
• Delays in obtaining renewal of regulatory approvals for the company's cGMP Facility and licenses could delay its development plans.
• The optimal donor and manufacturing parameters for the company's product candidates may have not been definitively established.
• The company has not yet developed a validated methodology of freezing and thawing large quantities of CTM-N2D, iPSC-gdNKT, CTM-GDT and CTM-MSC product candidates.
• The current tensions in international trade and rising international political tensions may adversely affect the company's business, financial condition, and results of operations.
• It is difficult and costly to protect the company's proprietary rights.
• The company is dependent on licensed intellectual property.
• The company may infringe the intellectual property rights of others.
• The company may become involved in lawsuits to protect or enforce its intellectual property.
• The company may not be able to obtain and enforce its intellectual property rights throughout the world.
• If the company fails to prevent disclosure of trade secrets and other proprietary information, the value of its technology and product could be significantly diminished.
• The company may elect to sue a third party, or otherwise make a claim, alleging infringement or other violation of patents, trademarks, trade dress, copyrights, trade secrets, domain names or other intellectual property rights that it either owns or licenses from a third party.
• The company may not identify or develop other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.
• The company has no experience as a company in obtaining regulatory approval for a drug.
• If the company fails to establish biopharmaceutical collaborations on commercially reasonable terms, or at all, it may have to change its development and commercialization plans.
• The company's product candidates could be subject to regulatory limitations following approval, if such approval is granted.
• There may be limited market opportunities for the company's product candidates, if approved.
• The commercial success of any of the company's product candidates will depend upon such product candidates level of market acceptance by physicians, patients, third-party payors and others in the medical community.
• Healthcare reform initiatives and other administrative and legislative proposals may affect the company's business.
• Obtaining and maintaining marketing approval or commercialization of the company's product candidates in one jurisdiction does not mean that it will be successful in obtaining marketing approval of its product candidates in other jurisdictions.
• The company has no prior business experience in India and is unfamiliar with Indian laws and regulations.
• If the company fails to comply with the regulatory standards of various regulatory agencies in manufacturing of quality products, it may have potential impact on its business, financials and operations.
• The assets acquisition of the cord blood stem cell banking facility in Malaysia may lead to unforeseen financial and operational difficulties.
• The company may face claims for infringing, misappropriating or otherwise violating intellectual property rights of third parties or engaging in unfair competition, which would be expensive and time-consuming, and could hinder the successful development and/or commercialization its product candidates.
• The company may fail to identify unauthorized use of its intellectual property and enforce its intellectual property rights against infringement, and may incur substantial costs as a result of bringing litigation or other proceedings to protect its intellectual property rights.
• The company may elect to sue a third party, or otherwise make a claim, alleging infringement or other violation of patents, trademarks, trade dress, copyrights, trade secrets, domain names or other intellectual property rights that it either owns or licenses from a third party.
• An active trading market for the company's ordinary shares or its ordinary shares may not continue and the trading price for its ordinary shares may fluctuate significantly.
• The company's ordinary share price may in the future be volatile and, as a result, you could lose a significant portion or all of your investment.
• If securities analysts do not publish research or reports about the company's business or if they publish negative reports or downgrade its shares, the price of its ordinary shares could decline.
• Sales of a substantial number of the company's ordinary shares in the public market by its existing shareholders could cause its share price to fall.
• The company's principal shareholders, officers and directors beneficially own approximately 70.80% of its outstanding ordinary shares.
• The company is a controlled company as defined under the Nasdaq Listing Rules.
• The company is an emerging growth company, and the reduced disclosure requirements applicable to emerging growth companies may make its Ordinary Shares less attractive to investors.
• The company is a foreign private issuer within the meaning of the rules under the Exchange Act, and as such it is exempted from certain provisions applicable to U.S. domestic public companies.
• The company may lose its foreign private issuer status, which would then require it to comply with the Exchange Acts domestic reporting regime and cause it to incur additional legal, accounting and other expenses.
• If the company's system of internal control over financial reporting is not effective and robust, its financial results may not be accurately reported and it may not be able to prevent fraud.
• The company's disclosure controls and procedures are not risk-free and may not fully prevent and/or identify errors or acts of fraud.
• The company incurs significantly increased costs and devote substantial management time as a result of operating as a public company.
• The company may face securities class action litigation.
• The company's results of operations may be affected by changes to, or interpretations of financial accounting standards may affect its results of operations, which may require it to change its business practices.
• The company's ability to use its loss carryovers and certain other tax attributes may be limited.
• Because the likelihood of paying cash dividends on the company's ordinary shares is remote at this time, investors must look solely to appreciation of its ordinary shares in the market to realize a gain on their investments.
• The company currently reports its financial results under IFRS, which differs in certain significant respects from U.S. GAAP.
• The company is incorporated in Singapore, and its shareholders may have more difficulty in protecting their interests than they would as shareholders of a corporation incorporated in the United States.
• The company's shareholders may have more difficulty transferring their shares in the Company.
• It may be difficult for you to enforce any judgment obtained in the United States against us, our Directors and officers and/or our affiliates.
• Subject to the general authority to allot and issue new ordinary shares as may be approved by our shareholders pursuant to the Singapore Companies Act and our constitution, our Directors may allot and issue new ordinary shares from time to time on such terms and conditions and for such purposes as may be determined by our Board of Directors in its sole discretion.
• We are subject to the laws of Singapore, which differ in certain material respects from the laws of the United States.
• Singapore take-over laws contain provisions that may vary from those in other jurisdictions.
• Our operations are affected by the changes in existing Malaysian laws and regulations, and the adoption of new Malaysian laws and regulations and/or the changes in interpretation of the Malaysian laws and regulations as well as possible inconsistencies between the various Malaysian laws and regulations and/or the corresponding interpretation
• We are subject to the political, economic and social conditions in the jurisdiction of Malaysia
• We are subject to the foreign exchange legislation and regulations in the jurisdiction of Malaysia
• Regulatory risks in relation to environmental hazards, production safety and the occurrence of accidents in Malaysia
• We may be subject to costs and risks associated with the monitoring, rehabilitation and compliance with environmental laws and regulations
• Compliance with PDPA Malaysia and any such existing or future data-privacy related laws, regulations and governmental orders may entail significant expenses, result in challenges with cross-border data transfers and could materially affect our business
• We are subject to regulations governing foreign workers in the event of employment of such foreign workers
• Mechanism for enforcement of foreign judgments in Malaysia is limited to certain jurisdictions
• If we fail to prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be materially diminished.

Future Outlook

CytoMed plans to continue its R&D efforts, advance its product candidates through clinical development, and expand its research pipeline. The company is targeting a Phase I clinical trial submission for CTM-MSC in the second half of 2025 and to recruit more patients in 2025 for the ANGELICA Trial.

Industry Context

The company operates in the competitive field of immunotherapy for cancer treatment, facing competition from well-funded biopharmaceutical companies and research institutions. The company is focused on developing novel off-the-shelf cell therapies to improve the quality of life of cancer patients and to increase their overall survival.

Comparison to Industry Standards

• The company's competitors in allogeneic CAR-T therapies include Allogene Therapeutics, Astellas Pharma, Bristol-Myers Squibb, Celyad Oncology, Fate Therapeutics, Gilead Sciences, NantKwest, Novartis, Surface Oncology, and Takeda Pharmaceutical.
• The company's competitors in gamma delta T cell therapy include TC BioPharm, Acepodia Biotech, and Adicet Bio.
• The company's competitors in iPSC-derived immune cells include Fate Therapeutics, Takeda-CiRA joint program, and Century Therapeutics.

Related Party Transactions

• Research income from Landmark Medical Centre Sdn Bhd (LMC) was S$115,277 in 2024.
• Dr. Lucas Luk Tien Wee, Chief Clinical Officer, is a shareholder and Chief Executive Officer of LMC.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial progress will impact shareholder value.
• Employees: The company's growth and R&D activities will impact employment opportunities and job security.
• Patients: The company's development of novel therapies has the potential to improve treatment options for cancer and degenerative diseases.
• Partners: The company's collaborations with research institutions and hospitals will impact the progress of clinical trials and commercialization efforts.

Next Steps

• Continue the ANGELICA Trial and recruit more patients in 2025.
• Pursue an investigational new drug application for CTM-GDT with the US FDA.
• Advance pre-clinical activities of product candidates.
• Target a Phase I clinical trial submission for CTM-MSC in the second half of 2025.

Key Dates

Keywords

CytoMed Therapeutics, financial results, clinical trials, immunotherapy, CTM-N2D, iPSC-gdNKT, CTM-GDT, CTM-MSC, biopharmaceutical, cancer treatment, regulatory approval, manufacturing, intellectual property, risk factors, Singapore, Malaysia